John Johnson

John Johnson is a declared insider at 5 companies (chief executive); the most frequent names are Xeris Biopharma Holdings, Inc., Axogen, Inc. and Strongbridge Biopharma plc. Between 2 July 2021 and 19 June 2026, the trades on record add up to 22 filings.

Sales make up the whole of the open-market record (4 sales, €1.9M). Besides market trades, the filings include 12 share grants and 4 option exercises.

Most recently, on 23 June 2026, the filings show an option exercise in Axogen, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.